NCT01951755已完成不适用
An Observational Study for Safety and Efficacy of Erlotinib Beyond 1st Line in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
University of Athens1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2012年1月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Progression Free Survival
研究概览
简要总结
An open-label, non randomized clinical trial of Tarceva as single agent in progressed non-small cell lung cancer patients.
详细描述
An observational non randomized clinical trial of Tarceva as single agent in progressed non-small cell lung cancer patients after chemotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological or cytological documented diagnosis diagnosis of inoperable, locally advanced, recurrent or metastatic (Stage IIIB or IV) NSCLC.
- •Patients must have evidence of disease but measurable disease is not mandatory.
- •18 years of age or older.
- •ECOG Performance Status of 0-
- •Life expectancy at least 12 weeks.
- •Patients with advanced stage IIIB/ IV NSCLC who have received at least one course of standard systemic chemotherapy or radiation therapy or who are in the investigator's opinion not medically suitable for chemotherapy or radiotherapy.
- •No more than 2 prior chemotherapy regimens are permissible. Patients must have recovered from any toxic effects and at least 3-4 weeks must have elapsed from the last dose and prior to registration (14 days for vinorelbine or other vinca alkaloids or gemcitabine). Patients who, in the opinion of the investigator, have fully recovered from surgery in less than 4 weeks may also be considered for the study. Patients must have recovered (CTC ≤ 1) from acute toxicities of any previous therapy.
- •Granulocyte count ≥ 1.5 x 109/L and platelet count > 100 x 109/L.
- •Serum bilirubin must be ≤ 1.5 upper limit of normal (ULN).
- •AST and/or ALT ≤ 2 x ULN (or ≤ 5 x ULN if clearly attributable to liver metastasis.
- •Serum creatinine ≤ 1.5 ULN or creatinine clearance ≥ 60 ml/min.
- •Able to comply with study and follow-up procedures.
- •For all females of childbearing potential a negative pregnancy test must be obtained within 72 hours before starting therapy.
- •Patients with reproductive potential must use effective contraception.
- •Written (signed) Informed Consent to participate in the study.
排除标准
- •Any unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, hepatic, renal or metabolic disease).
- •Prior therapy with systemic anti-tumour therapy with HER1/EGFR inhibitors (as small molecule or monoclonal antibody therapy).
- •Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).
- •Patients are excluded if they have brain metastasis or spinal cord compression that is newly diagnosed and/ or has not yet been definitively treated with surgery and/ or radiation; previously diagnosed and treated CNS metastases or spinal cord compression with evidence of stable disease (clinically stable imaging) for at least 2 months is permitted.
- •Any significant ophthalmologic abnormality, especially severe dry eye syndrome, keratoconjunctivitis sicca, Sjogren syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions. The use of contact lenses is not recommended during the study. The decision to continue to wear contact lenses should be discussed with the patient's treating Oncologist and the ophthalmologist.
- •Patients who cannot take oral medication, who require intravenous alimentation, have had prior surgical procedures affecting absorption, or have active peptic ulcer disease.
- •Nursing mothers.
结局指标
主要结局
Progression Free Survival
时间窗: 24 months
Defined as the time period from the entry to the study until assessed disease progression or death
次要结局
- Safety(Baseline, 4-6 months, 12 months, 24 months)
研究者
Kostas N Syrigos
Professor in Medical Oncology
University of Athens
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung CancerNon-Small Cell Lung CancerNCT02595450Hoffmann-La Roche299
已完成
2 期
A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT01996332Hoffmann-La Roche1,805
已完成
不适用
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung CancerNonsquamous Nonsmall Cell Neoplasm of LungNCT01161173Hoffmann-La Roche347
已完成
4 期
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease ProgressionNon-Small Cell Lung CancerNCT01230710Hoffmann-La Roche51
进行中（未招募）
不适用
A Phase II study of Tarceva® in Combination with Avastin® versus chemotherapy plus Avastin® in 1st line advanced NSCLC patients - TASKAdvanced Non-Small-Cell-Lung-Cancer (Stage IIIb and IV) 1st lineMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2006-006359-11-LTF. Hoffmann-La Roche200